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Diabetic retinopathy (DR) is a multifactorial progressive disease of the retina and a leading cause of vision loss. DR has long
been regarded as a vascular disorder, although neuronal death and visual impairment appear before vascular lesions, suggesting
an important role played by neurodegeneration in DR and the appropriateness of neuroprotective strategies. Upregulation of
vascular endothelial growth factor (VEGF), the main target of current therapies, is likely to be one of the first responses to
retinal hyperglycemic stress and VEGF may represent an important survival factor in early phases of DR. Of central importance
for clinical trials is the detection of retinal neurodegeneration in the clinical setting, and spectral domain optical coherence
tomography seems the most indicated technique. Many substances have been tested in animal studies for their neuroprotective
properties and for possible use in humans. Perhaps, the most intriguing perspective is the use of endogenous neuroprotective
substances or nutraceuticals. Together, the data point to the central role of neurodegeneration in the pathogenesis ofDR and indicate
neuroprotection as an effective strategy for treating this disease. However, clinical trials to determine not only the effectiveness and
safety but also the compliance of a noninvasive route of drug administration are needed.
1. Introduction
Diabetic retinopathy (DR) is a multifactorial progressive
disease of the retina with high social impact and with an
extremely complex pathogenesis that involves a variety of
different cells, molecules, and factors. Metabolic changes
in the diabetic retina result in altered expression pattern
of a number of mediators including growth factors, neu-
rotrophic factors, cytokines/chemokines, vasoactive agents,
and inflammatory and adhesion molecules, resulting in vas-
cular lesions and cell death [1–4]. In the recent past, DR was
generally considered a purely vascular disorder of the retina
and visual impairment was attributed to vascular damage. In
the last few years it has become evident that considerable
damage of retinal neurons is also present in early stages of
DR. As the investigations proceed and data are produced, it
appears that neurodegeneration also plays a significant role
in microvascular impairment [5–9].
The present review focuses on the possible causes and
the effects of neuronal damage in DR and discusses possible
approaches based on neuroprotection for the treatment of
this disease. In particular, with this review of the literature
we invite the reader to consider the following hypotheses:
(i) neuronal damage directly induced by diabetic stress may
be responsible for functional abnormalities in visual function;
(ii) a central role in linking neuronal damage to early micro-
vascular damage (i.e., vascular leakage) may be played by
VEGF expressed and released by damaged neurons; (iii)
therapeutic strategies based on neuroprotectionwill be useful
in preventing or arresting DR development.
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2. Neurodegeneration in DR and
the Role of VEGF
2.1. Evidence of Retinal Neuronal Damage in DR. There is
evidence that death of neurons appears before that of vascular
cells in the retina of both humans with DR and experimental
animal models of DR [10], while recent data in db/db diabetic
mice reported ganglion cell apoptosis, retinal thinning, and
ERGdeficits in the absence of obviousmicrovascular changes
[11]. These observations support the view that neuronal
damage is an early event in the pathogenesis ofDR [12, 13] and
that DR may be considered a neurodegenerative eye disease
[14]. Only in a few cases the occurrence of extensive neuronal
apoptosis in DR has not been fully acknowledged [15, 16]
and the only report excluding any loss of retinal ganglion
cells in DR is based on an analysis of cell numbers in the
GCL of retinal sections [17], which may have been unfit
to detect significant changes. Actually, the vast majority of
papers document the presence of apoptotic markers and/or
the appearance of functional defects in diabetic retinas.
In particular, apoptotic markers, including caspase-3 [18,
19], caspase-9 [19], Bax [18, 19], Bad [20], and Fas [18],
have been observed to increase in retinal ganglion cells of
patients with diabetes, while enhanced release of cytochrome
c and expression of apoptosis inducing factor has been
documented both in ganglion cells and in photoreceptor
cells [20]. Consistent with these findings, optical coherence
tomography (OCT) observations in patients with type 1
or type 2 diabetes revealed reduced thickness of the inner
retinal layers, which was only minimally associated with
vascular lesions [21–23]. Interestingly, a recent work, based
on a retrospective analysis of spectral domain OCT (SD-
OCT) scans of a number of subjects with diabetes and
with various stages of DR, shows that thinning of the inner
retina appears early in the pathology and before any visible
vascular signs of DR can be appreciated [24], suggesting
the opportunity of neuroprotective interventions to prevent
chronic neurodegeneration. Experimental data in animal
models of DR indicate that uncontrolled insulin-deficient
diabetes markedly increases neuronal cell death in the retina
[10, 25, 26]. For instance, in rats with streptozotocin-induced
diabetes, a significant increase in caspase-3 expression has
been reported in the nerve fiber layer, ganglion cell layer, and
inner plexiform layer as early as after twoweeks fromdiabetes
induction [27]. An increase in the cytosol concentration of
cytochrome c, secondary to the activation of caspase system,
has also been observed in streptozotocin-exposed rats after
8 months from treatment [28]. In addition, a significant
reduction of total retinal thickness and a decreased number
of ganglion cells together with increased active caspase-3 and
TUNEL labeling were reported in rat and mouse models of
type 2 diabetes [11, 29, 30]. Suffering of retinal neurons in
diabetic rodent retinas is also suggested by altered expression
of proteins involved in axonal transport in retinal neurons
[31] and by the decrease in the content of synaptic proteins
in retinal nerve terminals [32–34].
The neural cell types suffering alterations in early DR
have been studied in more detail in different rodent mod-
els of DR. A number of investigations reported increased
apoptosis of retinal ganglion cells [10, 26, 35–38]. Cholin-
ergic [39], dopaminergic [37, 39, 40], and neuronal nitric
oxide synthase-expressing [41] amacrine cells have been
also observed to be affected in DR. Interestingly, a recent
study reported significant reduction of dopamine levels in
rodent models of DR, while visual function was improved
by treatments with l-DOPA or with dopaminergic receptor
agonists [42]. In addition, alterations in retinal glutamatergic
and GABAergic systems are suggested by the observed early
transient changes in the content of glutamate and GABA
vesicular transporters in retinal synaptosomes [43]. Other
data documented photoreceptor death [37, 44, 45] and alter-
ations in the expression of phototransduction proteins [46],
while a reduction in photoreceptor density close to the fovea
has also been reported by a recent study in adult humans with
diabetes [47]. However, the data relative to photoreceptor
death or damage in diabetic retinas are not conclusive.
Indeed, a number of investigations in animal models of DR
reported lack of photoreceptor death and clinical studies
failed to convincingly demonstrate photoreceptor damage in
diabetic patients, as summarized in a recent review [48].
The presence of discrepancies about possible photoreceptor
damage in DR may be explained, at least in some cases,
assuming that observed photoreceptor loss or damage is due
to factors other than diabetes (for instance, strain differences,
in animal studies) or that the effects on photoreceptors are
critically dependent on the duration of diabetes.
In addition to changes in the cell bodies (e.g., TUNEL-
positive nuclei and caspase-3 activation, indicating apop-
tosis), defects in the processes of retinal neurons are also
evident in the retinas of rodent models of DR, and they
are represented mainly by abnormal swellings observed in
ganglion cell axons [49, 50] and morphologic changes in the
dendrites of ON-type ganglion cells [50]. Observed signs of
damage also include ganglion cell body swelling and axonal
fragmentation [50] and closely mimic the pathologic features
observed in postmortem human retinas from patients with
diabetes [51]. Impairments at the level of ganglion cell axons
are also documented by the finding of reduced efficiency
of both retrograde and anterograde axonal transports and
of reactive gliosis of axonal astrocytes in the optic nerve of
diabetic rats [52, 53].
The damage to retinal neurons in early phases of DR is
likely to be responsible for the functional deficits observed
both in animal models of DR and in patients with diabetes.
For instance, in diabetic db/db mice, retinal thinning and
ganglion cell apoptosis have been found to correlate with
pattern ERG alterations [11]. This assumption is also sup-
ported by the observations reported in a recent retrospective
case-control cohort study including eyes of diabetic patients
with resolved diabetic macular edema (DME) and eyes of
age-matched diabetic patients without maculopathy. Using
measures of retinal thickness, obtained with SD-OCT, and
measures of visual acuity, this study showed a significant
correlation between thinning of the ganglion cell layer and
visual acuity in patients with resolved DME, suggesting that
retinal alterations occurring in DME and DR may lead to
permanent visual deficiency [54]. Studies in animal models
showed that, in rats with experimentally induced diabetes,
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ganglion cells exhibit the greatest level of dysfunction within
the components of the electroretinogram (ERG) [55], while
significant decreases in the rod and cone ERG components
have been also reported [45, 56]. ERG abnormalities have
been reported in db/db diabetic mice [29], while ERG deficits
have been recorded in streptozotocin treated rats as early
as 2 weeks after diabetes induction [57], indicating that
functional abnormalities may be due to malfunctioning of
neurons starting well before the appearance of clear signs
of apoptotic cell death. In diabetic patients, earlier studies
reported abnormalities in the ERG [58] and, more recently,
a number of electrophysiological investigations in patients
with diabetes, but with no or mild signs of vascular damage,
have identified deficits of retinal functions in multiple layers
of the retina [59–63]. In addition, color vision and contrast
sensitivity are also affected in patients with diabetes [64, 65].
Electrophysiological and psychophysical observations have
recently reported abnormalities of retinal function in diabetic
patients without any evidence of microvascular changes [66].
In adolescents and young adults with type 1 diabetes but
without or with mild nonproliferative DR, as well as in
type 1 diabetic patients with normal ocular fundus and
absent breakdown of the blood-retina barrier, multifocal
ERG (mfERG) showed global retinal dysfunction [67, 68],
confirming that changes in retinal function occur before the
onset of vascular pathology.
Together, these data document the important role that
neurodegenerative phenomena may play in the retina of a
diabetic subject before the classical signs of DR are recog-
nizable and support the view that a neuroprotective strategy
should be considered for the treatment of patients before the
appearance of vascular lesions.
2.2. Possible Causes of Neurodegeneration in DR. A logic
consequence of the observation that neurons are damaged
in DR is the search for the possible causes of this fact. A
knowledge of the mechanisms that are likely to affect neu-
ronal survival in the diabetic retina is an essential prerequisite
to design therapeutic strategies aimed at reducing the impact
of diabetes on retinal neurons.
2.2.1. Advanced Glycation End-Products (AGEs). AGEs are
late products of nonenzymatic glycation. The deposition of
hyperglycemia-induced AGEs in retinal blood vessels plays
an important role in the onset and development of DR.
AGEs and their receptors (RAGEs) have been detected in
virtually all cellular types of the diabetic retina [69]. The
AGE-RAGE axis plays a central role in the inflammation and
microvascular dysfunction in DR [70], since AGEs have been
found to stimulate apoptosis of retinal pericytes [71, 72] and
of vascular endothelial cells [73, 74]. However, the potential
effects of these compounds on the survival of retinal neurons
are not fully elucidated. RAGE activation may induce retinal
neuron apoptosis through activation of nitric oxide synthase
[75] or may activate astrocytes and Müller glia promoting
the expression of proinflammatory cytokines [76] that would
contribute to neuronal death. A correlation between AGE
and neuronal death is suggested by the observations that
treatments reducing AGE formation also result in significant
reduction of neuronal death in retinas of db/db diabetic mice
[77] and that in diabetic rats AGE blockade prevents both
ERG abnormalities and ganglion cell apoptosis [78]. A direct
evidence of detrimental effects of AGEs on retinal neurons is
provided by results showing thatAGEs induce neuronal death
in nondiabetic retinal explants of both rat [79, 80] andmouse
[81] retinas.
2.2.2. Glutamate Excitotoxicity. Glutamate is the major exci-
tatory neurotransmitter in the retina and glutamate excito-
toxicity is the process damaging or killing neurons express-
ing NMDA or AMPA receptors due to excessive receptor
stimulation and calcium influx secondary to altered levels of
glutamate in the extracellular space. Elevated glutamate levels
have been observed in experimental models of diabetes [82–
84], where alterations of the expression of glutamate receptors
and calcium binding proteins have also been reported [85–
88]. An increase in glutamate levels has been detected in
the vitreous of patients with advanced DR [89, 90], while
an immunohistochemical analysis in human retinas of donor
eyes from subjects with diabetes described changes in the
expression of glutamate receptor subunits [91]. Together,
these data indicate that diabetes disrupts retinal glutamate
homeostasis and that in DR excitotoxic phenomena may
cause serious damage to retinal neurons. The reasons for
extracellular accumulation of glutamate in DR may involve
different mechanisms. For instance, Müller cells may become
less efficient in performing glutamate uptake [92] or in
converting glutamate to glutamine due to reduced levels of
the enzyme glutamine synthetase [82, 83], while a decreased
oxidation of glutamate to alpha-ketoglutarate has also been
reported in diabetic retinas [84].
2.2.3. Intracellular Pathways. The polyol pathway is activated
in the presence of elevated intracellular glucose levels and it
is linked with the progression of DR [93]. The rate-limiting
enzyme in this pathway is aldose reductase, which produces
sorbitol from glucose causing reduction of NADPH levels
and depletion of glutathione. This glutathione depletion and
the consequent increased oxidative stress aremajor inductors
of retinal damage. The polyol pathway also promotes other
mechanisms of cellular damage, including AGE formation
and activation of the protein kinase C (PKC) pathway, which
may lead to inflammation and growth factor imbalances [94].
Thus the polyol pathway can be regarded as a mediator of
glucose toxicity that is responsible for a wide spectrum of
abnormalities, including neural, glial, and vascular damage,
detectable during the development of DR [95]. In line with
this view, diabetic mice deficient in aldose reductase were
protected from diabetes-induced impairments in contrast
sensitivity and spatial frequency threshold [96]. In addition,
the cellular membranes are impermeable to sorbitol and
the inability of sorbitol to efflux out of the cell leads to its
intracellular accumulation, causing cellular damage mainly
due to osmotic imbalance. Although the exact mechanism of
sorbitol-induced cell death is still uncertain, this process is
likely to promote the progression of DR [97].
Poly(ADP ribose) protein (PARP), a nuclear enzyme
involved in the regulation of a variety of cellular events, is
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another potential inductor of retinal damage in DR. Indeed,
PARP is activated in diabetic retinas causing DNA damage
and oxidative stress [98–100], while its inhibition results in
increased neurotrophic support and reduction of neuronal
damage in early experimental DR [101].
Hyperglycemia and diabetes also increase the function of
the hexosamine biosynthetic pathway, which results in many
changes in both gene and protein levels, contributing to the
pathogenesis of DR [102]. In particular, the increased glucose
flux through the hexosamine pathwaymay cause apoptosis of
retinal neurons in twoways, that is, via induction of apoptosis
due to altered glycosylation of proteins or via impairment of
the neuroprotective effect of insulin mediated by Akt [103].
Activation of PKC is known to be implicated in several
pathologic changes occurring in DR, such as basementmem-
brane thickening, extracellular matrix expansion, vascular
permeability, apoptosis, angiogenesis, leukocyte adhesion,
and cytokine activation [2]. Similar to activation of the
hexosamine pathway, also PKC activation is likely to result in
retinal cell damage due to inhibition of insulin-induced Akt
activation [104].
2.2.4. Oxidative Stress. A considerable increase of oxidative
stress is known to occur in the diabetic retina [105, 106] and it
is the likely cause of neurodegeneration [107]. The metabolic
pathways discussed above are associated with mitochondrial
overproduction of reactive oxygen species (ROS); therefore,
oxidative stress may be regarded as a sort of final common
pathway for the glucose-induced abnormalities found in DR.
Oxidative stress may also result from nitrative stress [108,
109], activation of polyol or hexosamine pathways, or uncou-
pling of endothelial nitric oxide synthase [110]. In addition,
oxidative stress andAGEproduction appear to be interrelated
mechanism, since AGEs can induce oxidative stress through
direct or indirect stimulation of ROS generation, while AGE
synthesis is accelerated by oxidative stress [105, 111]. Similarly,
relationships between oxidative stress and glutamate release
have also been reported [84]. In summary, oxidative stress
is likely to increase the flux of polyol pathway as well as
AGE and RAGE expression, to induce PKC overactivation
and endothelial cell apoptosis and to promote inflammation
[105]. Enhanced ROS levels may also cause retinal neuronal
damage by reducing the expression of brain derived neu-
rotrophic factor (BDNF). Indeed, in retinas of mice with
streptozotocin-induced diabetes, reductions of both BDNF
and synaptophysin have been reported, but these reductions
were attenuated by the antioxidant lutein [107].
2.2.5.The Retinal Renin-Angiotensin System (RAS). Themost
well-known function of RAS is regulation of blood pressure
as well as of fluid and electrolyte content in the body. The
classical RAS is a systemic hormonal system, but local RASs
have been identified in a number of organs, including the
eye and the retina [112]. In DR, RAS is upregulated, with
increased levels of renin, angiotensin converting enzyme
(ACE), and angiotensin receptors (ATR) [113]. Retinal RAS
is likely to be implicated in the development of vascular
lesions in DR. Indeed, inhibitors of ACE, ATR, or aldos-
terone synthase reduce retinal neovascularization and VEGF
expression in rodent models of DR and some benefit of RAS
blockade in DR has been reported in clinical trials [114].
In retinas of diabetic animals, ACE inhibition and/or AT1R
blockade have been reported to attenuate functional deficits
[115–117] and to reduce oxidative stress, neurodegeneration,
and mitochondrial dysfunction [118], indicating that RAS
activation in DR may also affect retinal neurons.
2.2.6. Neuroinflammation. A considerable body of evidence
from animal models and patients shows that DR is a
chronic low-grade inflammatory disorder with participation
of inflammatory mediators [119]. Dysregulation of metabolic
pathways resulting in excessive mitochondrial ROS produc-
tion, increased oxidative stress, and RAS activation leads to
upregulation of a variety of growth factors and inflammatory
cytokines, chemokines, prostaglandins, and inflammatory
cells such as macrophages and neutrophils in a complex
chain of events. The resulting alterations decrease vascular
wall integrity, increasing vascular permeability, lumen occlu-
sion, and ischemia [119, 120]. Neuroinflammation involves
the activation of microglia and astroglia. In contrast to
microglia activation in acute inflammation, which may have
beneficial effects, in chronic neuroinflammation microglia
activation, resulting in release of proinflammatory media-
tors and increased oxidative stress [121], contributes to the
pathogenesis of neurodegenerative diseases [122]. While the
retinal microglia is likely to play important roles in DR, there
is also strong evidence that Müller cells are major sources
of inflammatory mediators [123] and become activated in
response to a variety of pathological changes in the retina
[124]. In particular, an analysis of gene expression in Müller
cells from retinas of diabetic rats revealed 78 altered genes,
of which one-third were associated with inflammation [125].
Sustained neuroinflammation creates a toxic milieu that
may lead to detrimental effects in neuronal cells [126, 127],
although the mechanisms by which these cytokines may
contribute to neural apoptosis in DR have not been fully
clarified.
2.2.7. Endoplasmic Reticulum (ER) Stress. ER stress results
from an impairment of the folding capacity of the ER
causing accumulation of unfolded proteins in the ER lumen
and activation of the unfolded protein response (UPR). ER
stress contributes to increased oxidative stress as well as
inflammation and apoptosis may occur upon failure of UPR
to resolve the ER stress.This condition is likely to be involved
in the pathogenesis of different neuronal diseases in brain
and retina, including the early stages of DR [128]. Disruption
of glutamate homeostasis with consequent glutamatergic
overstimulation, which has been described inDR (see above),
may activate ER stress and apoptosis in retinal ganglion
cells of mouse retinas [129]. In addition, data obtained using
streptozotocin-treated rats reported that the expression of ER
stress marker proteins in the retina is significantly increased
by diabetes and that reducing ER stress results in protection
of diabetic retinas from neuronal cell death and vascular
damage [130].
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2.2.8. Dysregulation of Endogenous Neuroprotectants. Insulin
provides trophic support for retinal neurons via phosphati-
dylinositide 3-kinase/Akt and P70S6 kinase pathways [131–
133]. This constitutive insulin prosurvival signaling in the
retina is impaired by diabetes andmay contribute to neuronal
degeneration in DR [134]. Similarly, insulin-like growth
factors (IGFs) are neurotrophic factors that may be involved
in the pathogenesis of DR. Indeed IGF-1 mRNA has been
found to be reduced in the eye in early stages of clinical and
experimental diabetes [135], while IGF replacement therapy
counteracts proapoptotic abnormalities preceding retinal cell
degeneration in diabetic rats [136].
Pigment epithelium-derived factor (PEDF) has been
described as a multifunctional protein with neuroprotective,
antiangiogenic, antivasopermeability, anti-inflammatory,
and antioxidative effects [137]. Its levels are decreased in
aqueous or vitreous of patients with diabetes, suggesting that
a decrease of retinal PEDF levels in humansmay contribute to
the development of DR [138]. Consistent with the hypothesis
that a reduction of PEDF may contribute to retinal neuronal
death in DR, in vitro studies in retinal Müller cells suggest
that PEDF could increase glutamine synthetase expression
and prevent downregulation of glutamate transporter in these
cells, thereby limiting glutamate excitotoxicity in the diabetic
retina [139, 140].
Alterations in retinal levels of neurotrophins (NTs) and
their receptors (tropomyosin receptor kinases, Trks, and
p75 neurotrophin receptor, p75NTR) may be present in
DR. Indeed, in the retina of streptozotocin-treated rats,
the upregulation of NT-3 and NT-4 and of their receptors
TrkA and TrkB is associated with the progression of DR
[141]. In addition, impaired maturation of the nerve growth
factor (NGF) precursor proNGF, caused by the oxidative
milieu of the diabetic retina, results in increased expression
of proNGF, with a corresponding decrease in NGF. The
dysregulation of proNGF maturation in the diabetic retina
may contribute to diabetes-induced retinal ganglion cell
death through the reduction in trophic support due to
decreased NGF expression or through the direct activation of
proapoptotic pathways in ganglion cells by proNGF interac-
tion with the p75NTR receptor [38, 142, 143]. Another pathway
by which proNGF may cause ganglion cell death involves
paracrine effects of proNGF/p75NTR-mediated secretion of
tumor necrosis factor-𝛼 by Müller cells [144]. Reduction of
retinal levels of BDNF has also been reported in animal
models of diabetes [40, 101, 107, 145], probably caused, at least
in part, by oxidative stress [107]. This reduction may affect
retinal neuronal survival, since exogenous supply of BDNF
has been found to reduce neurodegeneration in an animal
model of DR [40].
Interphotoreceptor retinoid-binding protein (IRBP) is
a photoreceptor-secreted glycolipoprotein that is essential
for photoreceptor survival [146]. IRBP levels are reduced
in the vitreous, while both IRBP mRNA and protein are
significantly lower in the retinas of donors with diabetes
than in those of nondiabetic donors [147, 148]. In addition,
IRBP levels have been found to be negatively correlated with
the levels of neurodegeneration in the retinas of patients with
diabetes [148].
The neuropeptide somatostatin (SST), together with its
receptors, is expressed in the retina, where it is involved
in a variety of functions [149]. A downregulation of SST
retinal expression has been reported in DR and it has
been found to be associated with retinal neurodegeneration
[150]. A decreased expression of SST in the retina results in
marked decrease of intravitreal SST in the eyes of patients
with proliferative DR [151, 152] or with diabetic macular
edema [153]. SST is likely to play a dual action in DR,
inhibiting both neoangiogenesis and neuronal death [149].
In particular, a major cause of neuronal death in diabetic
retinas is increased extracellular glutamate and excitotoxicity,
and SST may limit the extent of neuronal damage through
inhibition of glutamate release [154–157] and of glutamate
transporter downregulation [157].
2.3. VEGF: A Proangiogenic or a Neuroprotective Factor?
Observations of the brain after ischemia suggest that brain
damage, in addition to the activation of death pathways,
also stimulates protective mechanisms to counteract the
expansion of the injury. Although the damaging effectors
in the end prevail, the evidence suggests that concomitant
self-protective mechanisms are elicited, implying that the
central nervous system possesses intrinsic cytoprotective
mechanisms that are likely to be mediated by chemical
signals derived from the injured brain itself [158]. VEGFmay
be one of such signals released by the retina in the early
phases of DR. Indeed, we have shown that retinal neurons
in ex vivo ischemic retinas not only undergo cell death but
also express and release VEGF, which, in turn, is likely to
bind to its receptors expressed by endothelial cells [156,
159]. These observations indicate that VEGF expression and
release are among the earliest responses of suffering retinal
neurons and that, in this context, the significance of VEGF
release is unlikely to be related to its proangiogenic effects.
Rather, VEGF expression and release are probably related to
a protective strategy of the retina, which tries to protect its
cells from damage. Consistent with this view, glutamate exci-
totoxicity, one of the major causes of retinal neuronal death
in DR, has been reported to upregulate VEGF production in
diabetic retinas [160], while inhibition of NMDA receptors
results in a decrease in vitreoretinal VEGF in diabetic rats
[161]. In addition, we have recently observed that VEGF
expression and release markedly increase in retinal explants
within a few days of incubation in the presence of high
glucose, oxidative stress, or AGE and that these increases
are abolished or significantly reduced by the addition of
neuroprotectants [81]. Together, these observations suggest
that, in an early phase of DR, VEGF is likely to be expressed
and released to rescue and protect retinal neurons. In this
phase, VEGF would not act as a proangiogenic but as a
prosurvival factor. Interestingly, it has been reported that
the optic nerve and retinal ganglion cells in a rat model
of experimental glaucoma are protected from degeneration
by short-term hyperglycemia [162]. Increased VEGF levels
may negatively affect vessel permeability and the blood-retina
barrier. Then, if the stressing conditions remain for a long














Figure 1: Possible role of VEGF in early DR. Under diabetic stress, VEGF would be immediately released by neurons and by Müller cells,
which perhaps receive stimulation by the VEGF of neuronal origin. In the nonproliferative phase of DR (NPDR), released VEGF would act
on retinal neurons as a neuroprotectant, while it would also bind to its receptors on endothelial cells. A prolonged interaction of VEGF with
endothelial cells would lead to the proliferative phase of DR (PDR).
time, the persistent high levels of VEGF may lead to vessel
proliferation (Figure 1). In the retina, VEGF neutralization
has been reported to cause apoptosis of retinal cells and loss
of retinal function [163], while VEGF blockade has been
observed to significantly increase neuronal cell death in a
hypertensive glaucoma model [164]. Repeated intravitreal
injections of bevacizumab have been found to cause extensive
neuronal loss in the rat retina [165]. Furthermore, VEGF
has been found to be able to rescue retinal neurons after
optic nerve axotomy [166] and to play a role in the survival
of photoreceptors and of Müller cells [163]. Finally, using
organotypic retinal explants cultured in hypoxic conditions,
we have recently demonstrated that decreased VEGF release
is accompanied by increased retinal cell apoptosis, while
increased VEGF release results in reduced rate of retinal cell
death [167]. Therefore, the possibility exists that the VEGF
released by the retina in acute stress conditions, as we have
demonstrated in ex vivo ischemic models of the retina [156,
159], may have the scope of protecting retinal neurons rather
than that of promoting angiogenesis. One may wonder why,
despite high levels of VEGF expression and release in diabetic
retinas, neuronal death is still present, resulting in functional
abnormalities. The possibility exists that the diabetic milieu
may impair VEGF function uncoupling its survival effect,
as suggested by investigations with retinal endothelial cells
under high glucose or hypoxia [168, 169]. In addition, a shift
in VEGF splice variants reducing neuroprotective [170] and
increasing proangiogenic VEGF isoforms [171], as well as the
loss of other neuroprotective factors (i.e., somatostatin and
IRBP) induced by diabetes, is other mechanisms promot-
ing neuronal death even when an enhancement of VEGF
does exist. VEGF neuroprotective actions in the retina are
likely to be mediated by VEGF receptor 2 signaling via the
phosphoinositide-3-kinase/Akt pathway, as demonstrated in
different experimental models [164].
3. Therapeutic Perspectives for
Neuroprotection in DR
3.1. Methods for Detecting Retinal Neurodegeneration in the
Clinical Setting: A New Cornerstone for Clinical Trials?
Improvements in diabetes care and management have been
crucial in lowering the incidence and severity of DR. One
limiting factor that has hampered the investigation of new
drugs for DR is the low sensitive endpoints in the clinical
trials, which require large sample sizes as well as a long dura-
tion (about 5 years) to achieve a sufficient statistical power to
detect potential treatment effectiveness. Best corrected visual
acuity (BCVA) and derived variables are the only endpoints
that have served as the basis for regulatory approval of retinal
drugs.However, BCVA captures only a small portion of visual
function and patients with good BCVA may have difficulties
with daily activities such as reading or driving. Therefore,
there is nowwidespread recognition of the need for improved
endpoints for DR research.
Since neurodegeneration is an early event in the patho-
genesis of DR that could participate in the development
of microvascular impairment [14, 66], the study of the
underlying mechanisms leading to neurodegeneration and
the identification of mediators in the cross-talk between
neurodegeneration andmicroangiopathy are essential for the
development of new therapeutic strategies. Currently, the
presence of neurodegeneration can bemeasured by SD-OCT,
which allows the examination of morphological changes
(i.e., the thinning of the ganglion cell layer or of the nerve
fiber layer), or by means of functional methods such as
mfERG, standard automated perimetry, frequency doubling
perimetry, or microperimetry.
Among the methods for assessing the functional impair-
ment, the mfERG is the gold standard. This is a noninva-
sive technique providing a topographic measure of retinal
electrophysiological activity. The use of mfERG has pro-
vided compelling evidence suggesting a direct link between
neural dysfunction and vascular abnormalities in DR. Thus,
a delayed mfERG implicit time predicts the development
of early microvascular abnormalities [59, 172]. In addi-
tion, it should be noted that the implicit time is spatially
associated with microvascular abnormalities, correlates with
retinopathy severity, and is a predictor for the development
of visible vascular impairment over 1-year [173, 174] or 3-
year period [172]. However, mfERG is a time-consuming
and cumbersome examination and, consequently, its use is
currently limited to pilot studies and clinical trials.
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Figure 2: Potential therapeutic targets based on pathogenic mechanisms involved in retinal neurodegeneration induced by diabetes.
The current method for exploring the morphological
changes in retina is the SD-OCT, which provides an anatom-
ical image of the retina and complements the functional
information obtained with mfERG. The reduction in the
thickness of the ganglion cell layer and of the nerve fiber
layer are the main parameters detected in DR and they have
been observed even before any microvascular abnormality
appears in the fundoscopic examination [66].Hyperreflective
intraretinal spots (HRS) can also be found in diabetic eyes
without microangiopathy. HRS are mainly located in the
inner retina, where the resident microglia are present and
may represent a surrogate of microglial activation in the early
stages of DR [175]. At present, SD-OCT seems to be the most
practical method for monitoring neurodegeneration in DR.
In recent years a noninvasive instrument to assess mito-
chondrial function using flavoprotein autofluorescence has
been developed. This method is based on the fact that the
retina is particularly susceptible to oxidative stress because
of high energy demands and light exposure. Before apop-
tosis, mitochondria exhibit impaired electron transport by
energy generating enzymes in the respiratory chain, causing
increased percentages of flavoproteins in the chain to be
oxidized and rendered capable of absorbing blue light and
emitting green autofluorescence [176]. Since oxidative stress
and mitochondrial dysfunction are implicated in the patho-
genesis of DR, it is reasonable to expect that flavoprotein
autofluorescence may be used for monitoring retinal damage
[177]. However, clinical studies to validate this method are
needed.
3.2. New Therapeutic Strategies Based on Administration of
Neurotrophic Factors. There are several therapeutic strate-
gies based on the main pathogenic mechanisms involved
in retinal neurodegeneration that, theoretically, could be
implemented (Figure 2). However, systemically administered
drugs blocking these pathways can hardly reach the retina
at pharmacological concentrations and, in addition, could
have serious adverse effects. On the other hand, when the
early stages of DR are the therapeutic target, it would be
inconceivable to recommend an aggressive treatment such as
intravitreal injections. For all these reasons, topical treatment
could be envisaged as a revolutionary treatment.
The use of eye drops has not been considered an appropri-
ate route for the administration of drugs aimed at preventing
or arresting DR because of the general assumption that in
this way the drugs do not reach the posterior chamber
of the eye (i.e., the vitreous and the retina). However,
there is emerging evidence showing that several topically
administered compounds are able to reach the retina in
pharmacological concentrations, at least in animal models
[178–181]. In addition, topical administration of drugs limits
their action to the eye and minimizes associated systemic
effects [182].
Adherence to ophthalmic treatments has a unique set
of challenges compared to oral medications [183]. It must
be noted that self-administering drops (i.e., for glaucoma
treatment) requires coordination, manual dexterity, eye-
hand coordination, and good vision. In addition, diabetic
patients are commonly receiving a lot of treatments due
to the high prevalence of comorbidities. However, it must
be noted that a significant barrier to adherence is lack of
information (failing to explain the benefit of a medication
adequately). In this regard, it has been demonstrated that
patients are more likely to be adherent to their medication if
they understand the disease and the rationale for treatment.
Therefore, educating the patient and his/her family could
improve patient adherence to topical ocular therapy.
Pathologic conditions, including those characterizing the
diabetic status, are known to affect retinal levels of neuropro-
tective agents, thus impairing the balance between neurotoxic
and neuroprotective factors and resulting in damage to the
neural retina. In this respect, many different substances have
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been tested for their neuroprotective properties in models of
retinal stress similar to that in DR. Since a comprehensive
review of all the substances employed in experimental studies
is virtually impossible, we will briefly consider the potential
use in DR of endogenous neuroprotective substances or
of phytochemicals with antioxidant and anti-inflammatory
properties.
3.2.1. Endogenous Neuroprotective Substances. Insulin, IGF-
1, PEDF, SST, pituitary adenylate cyclase activating peptide
(PACAP), glucagon-like peptide- (GLP-) 1, and NTs are
potential neuroprotective factors for the treatment of DR.
Subconjunctival insulin administration restores prosur-
vival signaling and reduces the rate of retinal cell death in
streptozotocin-induced diabetic rats [184]. In this regard, it
has been reported that insulin hydrogels can be implanted
subconjunctivally for long term insulin delivery to the eye
without any adverse events in rats [185]. IGFs are neu-
rotrophic factors implicated in the pathogenesis of diabetic
neurological disorders and treatment with IGF-1 analogs
prevents early retinal biochemical abnormalities implicated
in the progression of DR [136].
PEDF is a peptide with neurotrophic properties produced
by retinal pigment epithelium cells and found to have neuro-
protective effects towards photoreceptors [186]. In addition,
systemic administration of PEDF to diabetic rats prevents
Müller cell activation and retinal dysfunction [187]. On the
other hand, PEDF is also a potent antiangiogenic factor [188]
and intravitreal PEDF effectively reduces VEGF-induced
vascular permeability in a mouse model of nonproliferative
DR [189]. In addition, PEDF also exerts antioxidant and anti-
inflammatory effects and reduces oxidative stress and the
production of inflammatory markers in DR models [190].
Moreover, in vitro studies in retinal Müller cells suggest
that PEDF decreases glutamate excitotoxicity induced by the
diabetic milieu by increasing the expression of glutamine
synthetase and by preventing glutamate transporter down-
regulation [139, 140]. Finally, intravitreal administration of
PEDF upregulates glutamine synthetase and glutamate trans-
porter expression and decreases glutamate levels in hypoxia
[191]. Taken together, these findings suggest that multitarget
molecules such as PEDF may be suitable candidates for
new therapeutic approaches to treat DR. However, PEDF
size may limit its utility as a topical therapeutic agent and,
therefore, some synthetic PEDF-derived peptides containing
biologically active fragments are needed. In this regard, the
amino acid residues of PEDF contributing to the inhibition of
VEGF-induced vascular permeability [189] and a PEDF frag-
ment inhibiting retinal vascularization in an oxygen-induced
retinopathy model [192] have been identified. Regarding
DR, the topical administration (eye drops) of antiangiogenic
PEDF60–77 and neuroprotective PEDF78–121 derivatives
reduced neurodegeneration andmicrovascular leakage in the
Ins2(Akita) mouse [193]. Furthermore, eye drop delivery of
PEDF-34 promotes ganglion cell survival and axon regener-
ation after optic nerve crush injury in rats [194].





) are expressed in the retina, where they are involved
in multiple functions [195]. SST acting at sst
2
expressed by
bipolar cells may control glutamate release in the retina
[154, 155, 196], suggesting that SST may protect neurons
from apoptosis caused by extracellular glutamate levels in
DR. In this respect, the first evidence has been provided
that topical administration of SST prevents retinal neurode-
generation in streptozotocin-induced diabetic rats [157]. The
main mechanism involved in this beneficial effect is indeed
the reduction of glutamate-induced excitotoxicity. With this
basis, a multicentric, phases II-III, randomized controlled
clinical trial (EUROCONDOR) to assess the efficacy of
SST administered topically (eye drops) to prevent or arrest
retinal neurodegeneration is ongoing (EudraCT number:
2012-001200-38).This study has been funded by the European
Commission in the setting of the FP7-HEALTH-2011 and the
results will be available in April 2016.
PACAP is known to be protective against a variety of
insults in mammalian retinas [197]. In particular, neuropro-
tective effects of PACAP against retinal cell loss induced by
ischemia have been reported both in vivo and in vitro [156,
198]. In addition, neurodegeneration of several retinal cell
types, including dopaminergic amacrine cells and ganglion
cells, is counteracted by PACAP in streptozotocin-treated rats
[37].
GLP-1 exerts neuroprotective effects in both central and
peripheral nervous systems [199]. It has been shown that
intravitreal injections of exendin-4 (a GLP-1R agonist) pre-
vent ERG abnormalities and morphological features related
to neurodegeneration in rats with streptozotocin-induced
diabetes [200] and in Goto-Kakizaki rats [201]. Recently,
abundant expression of GLP-1 receptor (GLP-1R) in human
retinas has been observed [202]. In addition, both neuropro-
tection andprevention of vascular leakage have been reported
using topical administration (eye drops) of GLP-1R agonists
in the db/db mouse model [202].
Originally identified as trophic factors for neurons, NTs
are a family of structurally and functionally related proteins
that are essential for the growth, differentiation, and survival
of several cell types including retinal neurons, glia, and
endothelial cells [144]. The main members of this family are
BDNF and NGF. In diabetic rats, retinal levels of BDNF
are decreased, and intravitreal administration of exogenous
BDNF rescues amacrine cells from neurodegeneration [40].
In addition, overexpression of BDNF in streptozotocin-
induced diabetic rats, obtained by intraocular injection of an
adenoassociated virus vector plasmid carrying the expression
cassette of brain BDNF, resulted in enhanced ganglion cell
survival and function [203]. The neuroprotective effect of
BDNF in the retina seems to be mediated, at least in part,
by prevention of the cytotoxic swelling of retinal glial and
bipolar cells [204]. NGF plays an important role in neu-
rodegeneration, inflammation, vascular permeability, and
injury, all important processes in the pathogenesis of DR.
There is no report on retinal production of NGF. However,
its administration in rat models of diabetes is effective in
counteracting retinal neurodegeneration. Indeed, intraocular
injections of NGF prevent apoptosis in retinal ganglion cells
and in Müller cells as well as pericyte loss and the formation
of acellular capillaries [205]. Recently, applications of NGF
as eye drops have been reported to protect retinal ganglion
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cells from degeneration in models of experimental glaucoma
or DR [206].
3.2.2. Antioxidant and Anti-Inflammatory Agents. Many
papers suggest that oxidative stress plays a major role in
the pathogenesis of DR. Therefore, the use of antioxidants
may be viewed as potential therapeutics in the treatment of
DR. Many phytochemicals have been extensively examined,
although much more work is needed to definitely assess their
effectiveness as alternative therapies in DR.
Flavonoids possess antioxidant, antiangiogenic, and anti-
inflammatory properties; thus selected flavonoids may be
effective in the prevention or treatment of ocular diseases,
including DR [207]. In this respect, quercetin reduces
oxidative stress, neuroinflammation, and apoptosis in strep-
tozotocin-treated rats. Indeed, six-month treatment with
quercetin restores glutathione levels and the activities of
antioxidant enzymes, reduces the levels of inflammatory
cytokines, and protects ganglion cells from apoptotic cell
death [208]. Numerous studies have investigated the role of
resveratrol in preventing or treating diabetic complications,
including DR. Four-month oral administration of resveratrol
to streptozotocin-treated rats partially prevents the decrease
in antioxidant defenses, retinal thinning, production of
inflammatory cytokines, and retinal cell apoptosis, without
affecting plasma levels of insulin [209, 210]. Resveratrol also
reduces retinal expression of genes involved in angiogenesis,
inflammation, and oxidative stress in diabetic rats [211]. The
antioxidant and antiangiogenic actions of curcumin have
been regarded as suitable characteristics in order to propose
curcumin as a novel drug for the treatment of DR. Two-
month administration of curcumin to streptozotocin-treated
rats inhibits the expression ofVEGF [212], while three-month
treatment with curcumin inhibits oxidative stress protects
Müller cells and prevents the downregulation of glutamine
synthase in the retina of diabetic rats [213]. A four-month
treatment with curcumin induces significant hypoglycemic
activity, reduces the decrease in glutathione levels and in
the activity of antioxidant enzymes, decreases inflammatory
factor levels, and prevents the structural degeneration and
increase in capillary basement membrane thickness in the
retina of diabetic rats [214]. Treatment with the flavonoid
hesperetin for six months rescues the retina from oxidative
stress, neuroinflammation, and apoptosis in diabetic rats
[215]. Genistein, administered to streptozotocin-treated
rats, attenuates retinal inflammation by targeting microglial
activation [216] and confers protection against gliopathy
and vasculopathy [217]. Interestingly, oral administration of
genistein in association with 𝛼-lipoic acid and vitamins to
preretinopathic diabetic patients, increases plasma levels of
antioxidants, and ameliorates electroretinographic record-
ings [218]. Finally, epigallocatechin gallate protects the retina
against glutamate toxicity through an antioxidantmechanism
in diabetic spontaneously hypertensive rats [219].
Carotenoids are also powerful antioxidants. In particular,
lutein and zeaxanthin, which in diabetes are decreased in
serum and retina, have been reported to inhibit diabetes-
induced retinal oxidative damage [220, 221]. Treatment with
zeaxanthin has been tested in a large trial on age-related
macular degeneration with moderate success [222].
Overall, data from literature indicate phytochemicals (not
only flavonoids or carotenoids, as briefly described here, but
also phenolic acids, terpenoids, etc.) as effective molecules
in the management of retinal complications in diabetes,
although further investigations using human clinical studies
are needed to confirm the beneficial effects of phytochemicals
in the treatment of DR.
Given that diabetic murine models do not develop
advanced vascular abnormalities, the experimental studies
mentioned above have demonstrated the usefulness of neu-
roprotective agents to prevent the development of retinal
neurodegeneration and initial vascular leakage. Although
it could be reasonable to speculate that neuroprotection
of the retina will be useful at any stage of DR, further
evidence demonstrating this issue is needed. In particular,
more work both in animal models, using sufficiently large
numbers of animals to have statistical power, and in the
clinics is necessary to provide conclusive demonstration that
neuroprotection not only preserves neurons from death or
damage but also results in actual functional improvements.
3.3. Other Approaches
3.3.1. Improving the Neurovascular Coupling Function. Alter-
ations of the neurosensory retina and retinal vasculature are
integrally linked, and the study of the interactions between
blood vessels and the neurosensory retina is crucial to under-
stand the pathogenesis of DR. Neurovascular coupling is the
intrinsic physiological mechanism by which neural activity
is coupled to blood flow and metabolism, thus enabling the
retina to regulate blood flow in response to neural activity or
metabolic demands. Indeed, the increased delivery of oxygen
in response to the increased activity of retinal neurons is
a consequence of the coupling between neural activity and
the vasculature. The neurovascular coupling in the retina is
altered in diabetes [223].
Visual stimulation is a powerful modulator of retinal and
optic nerve blood flow [224]. Since the blood vessels do not
directly respond to light, light-induced changes in blood flow
or oxygen deliverymust be initiated by light-induced changes
in neural activity of the retina. An increase of neural activity
leads to retinal arterial and venous dilation [225]. Flicker light
stimulation (intermittent flash) has been used to investigate
this process, which results altered in diabetic patients without
structural microvascular abnormalities in the retina [226–
228].
The retina has a high metabolism and O
2
consumption
and, therefore, is particularly susceptible to hypoxia caused
by compromised bloodflow.The loss of this vascular response
could starve the retina of needed oxygen and glucose, putting
neurons at risk and contributing to retinal pathology. The
improvement of functional hyperaemia could be a useful
therapeutic target. In this regard, it has been demonstrated
that blocking inducible nitric oxide synthase with systemic
administration of aminoguanidine recovers flicker-evoked
vasodilation in diabetic retinas [229].
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Among the mediators of the hemodynamic impairment
of the neurovascular coupling that occurs in diabetic patients,
endothelin seems to play a significant role. It should be
noted that endothelin 1 (ET-1), a potent vasoconstrictor, is
overexpressed in endothelial cells in the setting of DR and
enhances glutamate-induced neurotoxicity in retinal neural
cells [230, 231]. In addition, it is worth mentioning that,
through ETB receptors, ET-1 contributes to retinal ganglion
cell loss in ratmodels of glaucoma and optic nerve injury [231,
232]. Moreover, progressive retinal neurodegeneration has
been found in transgenicmice with an overexpression of ET-1
in vascular endothelial cells [233]. Finally, it has been recently
demonstrated that the blockade of ETA receptors, apart
from ameliorating retinal vascular pathology by reducing
pericyte loss and acellular capillaries, prevents thinning in
both the optic nerve and retinal periphery in db/db mice
[234]. Therefore, ET-1 seems to be a key player involved
in the cross-talk between neurodegeneration and vascular
abnormalities in the setting of DR. For this reason, the
inhibition of ET-1 could lead not only to an improvement
in microvascular hemodynamics in the retina, but also to
an amelioration of the retinal neurodegeneration associated
with diabetes. However, clinical trials are needed to confirm
these experimental findings.
3.3.2. Blocking Glutamate Signaling Pathway. Since the extra-
cellular accumulation of glutamate plays a key role in reti-
nal neuron death, treatments addressed at reducing glu-
tamate levels seem appropriate. In this regard, substances
targeting the glutamate receptors, such as memantine, have
shown beneficial effects on neurodegeneration and vascular
abnormalities in streptozotocin-induced diabetic rats [235].
Memantine has failed in demonstrating neuroprotection in
phase III clinical trials for glaucoma [236]. However, since the
pathophysiology of retinal neurodegeneration is different in
diabetes and glaucoma, specific studies examining whether
or not memantine may exert a neuroprotective effect in the
diabetic retina are needed.
3.3.3. Cell-Based Therapies. Several potential therapies using
endothelial precursor cells have been explored. However, the
usefulness and safety of these approaches for DR remain to be
determined. Regarding retinal development and transplanta-
tion strategies, the last decade has seen an enormous progress
in the research for photoreceptor replacement and regenera-
tion [237]. Restoration of visual function by cell replacement
seems to be a real possibility for neurodegenerative diseases
such as retinitis pigmentosa.
4. New Perspectives
The advances in both retinal imaging and functional assess-
ment will allow detecting early changes and will accelerate
drug discovery and delivery strategies to improve visual prog-
nosis in diabetic patients. In addition, this new approach will
encourage the implementation of personalized treatments. In
this regard, OCT angiography and confocal adaptive optics
scanning ophthalmoscope (AOSLO) are two new technolo-
gies thatwill play a key role in the near future for the diagnosis
and monitoring of treatments in early stages of DR. OCT
angiography proved to be capable of showing 10micron-thick
blood vessels, revealing the areas of vascular nonperfusion
and identifyingmicroexudates thatwere not otherwise visible
on clinical examination and fundus photography. Moreover,
OCT angiography allows appreciation of spatial relationships
of fundus vessels and makes it possible to separately visualize
the large retinal vessels as well as the superficial and the
deep capillary plexus [238]. Adaptive optics imaging can
be expected to add new aspects to the knowledge of DR
because photographic resolution has improved by reducing
the influence of optical aberrations on retinal imaging [239].
The confocal AOSLO allows seeing details of themicrovascu-
lature, photoreceptors, and hemorheologic parameters and,
therefore, is a promising noninvasive and direct method for
examining physiopathological events that are taking place in
the retina of diabetic patients and may be used for evaluating
the effects of clinical interventions [239, 240]. In this regard,
clinical trials aimed at examining the effect of controlling the
risk factors and new treatments on the diameter of retinal
vessels and blood flow would be of particular interest.
From the therapeutic point of view, as previously men-
tioned, when the early stages of DR are the therapeutic
target it would be inconceivable to recommend an aggressive
treatment such as intravitreal injections.There is experimen-
tal evidence that topical administration is effective for the
treatment of early stages of DR [157, 194, 202]. Therefore,
the topical route of drug delivery for the treatment of DR
could be envisaged as a revolutionary treatment, particularly
at the early stages of the disease. However, less than 5% of
topically applied dose reaches the deeper ocular tissues [241].
To overcome the ocular drug delivery barriers and improve
retinal bioavailability, conventional and novel drug delivery
systems are being developed.
In conclusion, the central role of neurodegeneration
in the pathogenesis of DR is a solid basis for proposing
neuroprotection as an effective strategy for preventing or
arresting DR. However, clinical trials to determine not only
the effectiveness and safety, but also the compliance of a non-
invasive route of drug delivery, as well as a standardization of
the methods for monitoring neurodegeneration, are needed.
In addition, neuroprotection in the setting of DR should be
contemplated as an early treatment; therefore, this exciting
experimental approach seems to be still far from acceptance
in clinical practice.
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study was supported by grants from the Italian Minis-
tero dell’Istruzione, dell’Università e della Ricerca, from the
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